Articles

The FDA has revoked its previous accelerated (and conditional) approval for bevacizumab (Avastin, Genentech) for the treatment of metastatic breast cancer (MBC), citing safety concerns that outweigh its benefits in this patient population.

5-Year Analysis of VISTA Confirms Survival Advantage with Bortezomib for Patients with Myeloma

By Audrey Andrews

ASH 2013 Annual Meeting

December 2011, Vol 2, No 7

Patients with multiple myeloma receiving bortezomib (Velcade) in the pivotal VISTA trial lived more than 1 year longer than those in the control group, according to the final, 5-year analysis of the study presented at the 2011American Society of Hematology annual meeting.

Dual HER2 Blockade with Pertuzumab Substantially Delays Disease Progression

By Caroline Helwick

CTRC-AACR SABCS Annual Meeting

December 2011, Vol 2, No 7

San Antonio, TX—It is becoming increasingly clear that 2 agents are better than 1 in treating HER2-positive advanced breast cancer.

GPCI, or “GYPSY”: Calculated or Covert Cuts to Oncology Reimbursement

By Robert Gamble

Health Policy, Policies & Guidelines

December 2011, Vol 2, No 7